Investors

Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures in both the hospital and home settings.

NASDAQ: MRNS
$ 1.71 +0.03 (1.79%)
Day High: 1.73
Day Low:  1.64
Volume:    272,544
4:00 PM ET
Jul 21, 2017

Delayed ~20 min., by eSignal.